Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric K Rowinsky

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
The Oncologist|August 20, 2002
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?Eric K Rowinsky
European Journal of Cancer (Oxford, England : 1990)|September 16, 2005
Erosion of the principal investigator role in a climate of industry dominanceEric K Rowinsky
Annual Review of Medicine|January 30, 2004
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitorsEric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agentsEric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignanciesEric K Rowinsky
The Oncologist|December 13, 2003
Signal events: Cell signal transduction and its inhibition in cancerEric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignanciesEric K Rowinsky
Current Opinion in Oncology|January 1, 2005
Targeting the molecular target of rapamycin (mTOR)Eric K Rowinsky
Clinical Lung Cancer|January 11, 2005
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugsEmiliano Calvo, Eric K Rowinsky
Current Oncology Reports|February 19, 2005
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptorEmiliano Calvo, Eric K Rowinsky
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
The Oncologist|August 20, 2002
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?Eric K Rowinsky
European Journal of Cancer (Oxford, England : 1990)|September 16, 2005
Erosion of the principal investigator role in a climate of industry dominanceEric K Rowinsky
Annual Review of Medicine|January 30, 2004
The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitorsEric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agentsEric K Rowinsky
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignanciesEric K Rowinsky
The Oncologist|December 13, 2003
Signal events: Cell signal transduction and its inhibition in cancerEric K Rowinsky
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignanciesEric K Rowinsky
Current Opinion in Oncology|January 1, 2005
Targeting the molecular target of rapamycin (mTOR)Eric K Rowinsky
Clinical Lung Cancer|January 11, 2005
Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugsEmiliano Calvo, Eric K Rowinsky
Current Oncology Reports|February 19, 2005
Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptorEmiliano Calvo, Eric K Rowinsky
Pageof 12